What Has Changed
The second Trump administration’s patent reforms have jolted the landscape, empowering USPTO Directors with gatekeeping muscle and proposing curbs on serial PTAB challenges that ripple into federal courts. Since early 2025, bifurcated institution decisions, workload-weighted denials, and rulemaking have slashed IPR access, prioritizing “reliability” over volume. Practitioners must pivot: Challengers face higher bars, owners gain defensive fortitude, and district strategies demand tighter PTAB sync.
Historical Pivot and Core Changes
Post-AIA (2011), PTAB flooded with 20,000+ petitions yearly, prompting abuse fixes like 2019’s SAS (full claim reviews) and Biden-era Fintiv discretion. Trump’s return amplified this: March 26, 2025 interim procedure bifurcates IPR/PGR institution—Director first vets discretionary denial via streamlined briefing (owner: 2 months post-filing; petitioner: 1 month reply). Merits panels follow only for greenlit cases. Denial now explicitly factors PTAB backlog and AIA deadlines, correlating with 2025’s institution dip (per PTAB Year in Review).
October 2025’s proposed rules target IPR: Mandatory stipulations waiving duplicate anticipation/obviousness elsewhere; IPR bans post-validity rulings (district/ITC/USPIO); timing limits amid litigation. Life sciences spared broader PGR applicability.
Federal Court and Litigation Overhaul
PTAB hurdles reshape Article III playbooks. Parallel suits now fuel denials; owners tout Fintiv in briefs to quash stays.
| Pre-Reform | Reform Reality | Tactic Shift |
|---|---|---|
| IPR stay routine | Denial risk high | Stipulate grounds early |
| Serial multi-petitions | Curbed repeats | Single “killer” petition |
| Post-trial IPR | Often viable | Barred if validity upheld |
Hypothetical: Petitioner targets software patent amid district suit. Bifurcated brief highlights Fintiv factors + workload; Director denies. Outcome: District stay denied, forcing merits fight—challenger settles higher.
Sector-Specific Fallout
Life Sciences: Post-ITC validity shields IPRs; mRNA owners leverage for biosimilar blocks. E.g., CRISPR portfolios harden, enforcement injunctions rise 15%.
Software/Tech: §101 serials squeezed; Alice motions surge in W.D. Tex. Firms like Apple coordinate stipulations for hardware-software hybrids.
Manufacturing: Mechanical patents benefit from backlog priority; auto suppliers see fewer challenges, boosting licensing.
Clean Tech: Policy “innovation” tilt aids enforcement amid IRA subsidies.
Enforcement/Defense Evolution
Owners: Reliable patents fuel aggressive suits—NDCal injunction grants up. Challengers: Declaratory preemption or reexams as IPR backups.
Case Study: Pharma Defense
Owner faces obviousness IPR post-district win. Stipulation bar + prior ruling trigger denial; firm parleys into favorable license. Absent reform: Repeat attack likely succeeds.
Jason A. Lief’s Actionable Strategies
Windels Marx’s Lief webinar distills must-haves:
Owners’ Step-by-Step Defense:
Filing alert: Trigger denial brief calendar.
Argue equities: Parallel posture, priors, backlog impact.
Integrate: Use denial in district anti-stay motion.
Portfolio: Annual serial-risk audit.
Challengers’ IPR Launch Guide:
Pre-petition: Stipulation modeling, Fintiv audit.
Bifurcated prep: Denial rebuttal + merits parallel tracks.
Contingency: District DJ if denied; ex parte fallback.
Multi-party: Joint stipulations to dodge “serial.”
Settlement Pro Tip: Post-Director decision = prime window.
2026 Outlook and Adaptation Roadmap
Final rules expected Q2 2026; expect pharma carve-outs. Roadmap:
Track: Federal Register, PTAB dashboard.
Simulate: Mock bifurcations in CLE.
Tool Up: Lex Machina for denial predictors.
Collaborate: AIPLA policy committees.
Measure: Institution success KPIs.
Reforms cement pro-owner tilt—adapt or lag.
How are bifurcated briefs reshaping your PTAB practice?
References:
1. https://www.ballardspahr.com/insights/alerts-and-articles/2025/03/uspto-procedure-adds-new-hurdle-to-ptab-trial-institution
2. https://ipwatchdog.com/2025/03/26/uspto-director-takes-over-requests-for-discretionary-denial/
3. https://www.federalregister.gov/documents/2025/10/17/2025-19580/revision-to-rules-of-practice-before-the-patent-trial-and-appeal-board
4. https://www.sternekessler.com/news-insights/insights/outlook-for-2025-how-trump-and-the-uspto-will-affect-life-sciences-ip-2/
5. https://www.sternekessler.com/news-insights/insights/ptab-year-in-review-a-shifting-landscape-and-outlook-for-2026/
6. https://www.ropesgray.com/en/insights/alerts/2025/01/expected-changes-to-ip-policy-under-the-second-trump-administration